Springboard Enterprises Announces Inaugural 2024 Healthcare and Technology Accelerator Program Cohort
October 2, 2024
WASHINGTON, DC, UNITED STATES, September 11, 2024 /EINPresswire.com/ — Springboard Enterprises, a leader in fostering women-led innovation, is proud to announce its 2024 Healthcare and Technology Cohort. The nine selected companies, led by innovative female founders, are addressing key areas in healthcare such as cancer diagnostics, antimicrobial resistance, and at-home diagnostics, each contributing solutions to improve patient care and outcomes.
These companies will participate in Springboard’s Healthcare and Technology accelerator program with an intensive bootcamp and a series of expert-led workshops designed to accelerate the participating companies’ growth. Springboard Enterprises’ accelerator programs provide access to a dynamic network of strategic advisors and experts, helping founders drive innovation and navigate the next phase of their journey.
Digital Health funding has seen a notable rebound in the first half of 2024, with $12.4 billion invested across 719 deals – a 5% increase compared to 2023. This growth has been driven by advancements in AI in healthcare, health management, and medical diagnostics. Key trends include a surge in mega deals and strong M&A activity, particularly in the U.S., demonstrating resilience in the market despite broader economic challenges¹.
“We are thrilled to introduce our 2024 Healthcare and Technology Cohort, a group of dynamic entrepreneurs who will make an impact in the healthcare industry. These companies bring innovative solutions to some of the most pressing health challenges, from cancer diagnostics to combating antimicrobial resistance. By pairing them with our experienced advisors and providing access to our extensive network, we are ensuring these innovators have the tools they need to drive meaningful change in the healthcare ecosystem.”
Julie Silverstein – Acting CEO, Springboard Enterprises
The nine companies selected for the 2024 cohort are:
1. Jean Pham, Co-Founder & CEO, Cellens
Cellens is bringing clarity and precision to non-invasive cancer diagnostics through the combination of mechanobiology and machine learning, creating a powerful tool to aid in early detection.
2. Cheri Ackerman, Co-Founder & CEO, Concerto Biosciences
Concerto Biosciences uncovers the complexities of microbial ecosystems, providing insights that fuel microbial product discovery for healthcare applications.
3. Julie Kennedy, Co-Founder & CEO, RubyWell
RubyWell is an intelligent, automated guide that helps family caregivers regain financial stability by continuously discovering and delivering new savings, benefits, and compensation opportunities.
4. Amanda Burkardt, CEO, Phiogen
Phiogen is developing the next generation of antibiotics to combat antimicrobial resistance (AMR) and treat hard-to-manage infections.
5. Pahini Pandya, Founder & CEO, Panakeia Technology Limited
Panakeia’s AI platform delivers molecular biomarker information directly from H&E tissue images in minutes, offering life-saving benefits to cancer patients by speeding up diagnostic timelines.
6. Martha Sklavos, PhD, Founder & CEO, Aloe Therapeutics
Aloe Therapeutics harnesses the power of the immune response from transplant rejection to boost the effectiveness of checkpoint immunotherapy for patients with difficult-to-treat solid tumors.
7. Amy Urban, DMD, Founder & Chief Medical Officer, Urban Innovations
Urban Innovations is a women-owned medical device company focused on improving sleep quality through non-pharmacological solutions.
8. Nathalya Mamane, Founder & CEO, RT MicroDx
RT MicroDx offers accurate, accessible, at-home diagnostics using saliva-based DNA amplification technology to detect bacterial and viral pathogens, starting with Strep A.
9. Adrianna Cantu, Founder & CEO, Revealix
Revealix provides a mobile smart foot health platform using thermography and risk screening software to prevent diabetic foot complications, particularly benefiting rural and underserved areas.
Mary Keslo
Springboard Enterprises
email us here
Visit us on social media:
LinkedIn
Instagram
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
